加格列净(分子式:C25H29ClO6,化学名:(1S)-1,5-脱水-1-C-[3-[4-[(1α,3α,5α)-双环[3.1.0]己-3-基氧基]苄基-4-氯苯基]-D-葡萄糖醇)是一种由四环医药研发的实验性SGLT2抑制剂[1]用于治疗糖尿病[2]

加格列净
法律规范状态
法律规范
  • Investigational
识别信息
CAS号1800115-22-3  checkY
UNII
化学信息
化学式C25H29ClO6
摩尔质量460.95 g·mol−1
3D模型(JSmol英语JSmol
  • O([C@@H]1C[C@@]2([C@@](C2)(C1)[H])[H])C3=CC=C(CC4=CC(=CC=C4Cl)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C=C3

它可以2-氯-5-溴苯甲酸3-环戊烯-1-醇为原料,经多步反应制得。[3]

参考文献

编辑
  1. ^ Song, Ling; Yao, Xueting; Liu, Yang; Zhong, Wen; Jiang, Ji; Liu, Hongzhong; Zhou, Huimin; Shi, Chongtie; Zong, Kaiqi; Wang, Chong; Ma, Chuanxiang; Liu, Dongyang; Hu, Pei. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European Journal of Pharmaceutical Sciences. April 2020, 147: 105281. doi:10.1016/j.ejps.2020.105281. 
  2. ^ 惠升生物加格列净片. 四环医药. [2023-12-14]. (原始内容存档于2023-12-14). 
  3. ^ Wu, Frank. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus). 2015. EP2891654.